5398722026-04-012026-06-305398722026-06-305398722026-04-012026-06-30in-capmkt:OtherExpenses1Member5398722026-04-012026-06-30in-capmkt:OtherExpenses2Member5398722026-04-012026-06-30in-capmkt:OtherExpenses3Member5398722026-04-012026-06-30in-capmkt:OtherExpenses4Member5398722026-04-012026-06-30in-capmkt:OtherExpenses5Member5398722026-04-012026-06-30in-capmkt:OtherExpenses6Member5398722026-04-012026-06-30in-capmkt:OtherExpenses7Member5398722026-04-012026-06-30in-capmkt:OtherExpenses8Member5398722026-04-012026-06-30in-capmkt:OtherExpenses9Member5398722026-04-012026-06-30in-capmkt:OtherExpenses10Member5398722026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15398722026-06-30Statement15398722026-04-012026-06-30Statement15398722026-06-30StatementDynamic1I1Statement15398722026-06-30StatementDynamic1I2Statement15398722026-06-30StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2026-04-012027-03-312026-07-202026-07-14INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2026-07-2017:00:002026-07-2017:31:00Not applicabletrue1falseDuring the quarter ended 30 June 2026, there has been no default of any loan or debt securities.2026-04-012026-06-30UnauditedStandalone1656317000811400016644310009158910000-54924000174712000609100007013800033312100014998480001645830000164583000025655000256550000138928000-2603000-655000-19480000136980000224500013922500016831300054.134.12-0.06-0.064.074.060.462.47343.70211. The above financial results of Bajaj Healthcare Limited (the Company) have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 20 July 2026. These results have been subjected to a limited review by the statutory auditors who have expressed an unmodified review conclusion. <br /> <br /> 2. The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. <br /> <br /> 3. The above unaudited financial results for the quarter ended 30 June 2026 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS)as prescribed under Section 133 of the Companies Act 2013 (Act) read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI (Listing obligations and disclosure requirements) Regulations 2015 as amended. <br /> <br /> 4. The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore the Company has identified only one reportable segment i.e. Pharmaceuticals. <br /> <br /> 5. In the year ended 31 March 2024 the Board of Directors had approved to sale disposal of undertaking unit(s) on going concern basis situated at plot no. N 92, L 9 3, T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 and D 2 CH 43 Dahej industrial area GIDC Bharuch Gujarat (which were acquired under SARFAESI ACT 2022 from Saraswat Bank) and plot no.E 62 and E 63 MIDC Tarapur Taluka Boisar District Palghar Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale disposal under Ind AS 105 (Non-current Assets Held for Sale and Discontinued Operations). The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and L 9 3 was sold during the Quarter ended 31 March 2026. The total value of assets classified as held for sale represents lower of carrying value or fair value. <br /> <br /> The financial information from discontinued operations: <br /> Particulars Quarter Ended Year ended <br /> 30 June 2026 31 March 2026 30 June 2025 31 March 2026 <br /> (Unaudited) (Refer Note 2) (Unaudited) (Audited) <br /> Total Income ( A ) 10.61 2.10 11.71 <br /> Total Expenses ( B ) 26.03 240.79 47.53 523.40 <br /> Loss before Tax from Discontinued Operations ( C A B ) (26.03) (230.18) (45.43) (511.69) <br /> Tax Credit from Discontinued Operations ( D ) (6.55) 113.60 (11.43) 42.74 <br /> Loss after Tax from Discontinued Operations ( E = C D ) (19.48) (343.78) (34.00) (554.43) <br /> <br /> 6. On 19 September 2024 the Company allotted 3984852 equity shares and 2079409 convertible warrants raising an aggregate amount of Rs. 15225.90 lakhs. This included 25 percent of the warrant issue price amounting to Rs. 1757.10 lakhs received at the time of allotment of the convertible warrants. <br /> During the quarter ended 31 March 2026 the Company received the balance 75 percent of the warrant issue price aggregating Rs. 5271.30 lakhs. Subsequently the Board of Directors at its meeting held on 18 March 2026 approved the conversion of all 2079409 convertible warrants into an equivalent number of fully paid up equity shares of face value Rs. 5 each. <br /> Pursuant to the aforesaid conversion the issued subscribed and paid up equity share capital of the Company increased from Rs. 1579.16 lakhs comprising 31583252 equity shares of face value Rs. 5 each to Rs. 1683.13 lakhs comprising 33662661 equity shares of face value Rs. 5 each. <br /> During the quarter ended 30 June 2026 the Company received approvals from the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) for the listing and trading of the aforesaid 2079409 equity shares of face value Rs. 5 each. <br /> <br /> The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. <br /> <br /> Particulars Amount to be Utilised Utilised up to 30 June 2026 Unutilised Balance <br /> Repayment of loan 15000.00 15000.00 0.00 <br /> Investment in capital expenditure 3500.00 2330.84 1169.16 <br /> General corporate purposes 1997.00 1993.48 3.52 <br /> Total 20497.00 19324.32 1172.68 <br /> <br /> 7. The Company had entered into a Transfer of Technical Know how arrangement with a customer for one of the products manufactured by the Company. The Technical know how was ultimately to be used by a customer in Middle East. Due to on going regional instability in Middle East the customer was not able to meet its committed timeline. Hence the Company has reversed the income recognised in earlier year amounting to Rs. 3324.66 lakhs in the quarter ended 31 March 2026. <br /> <br /> 8. In April 2025 the Company acquired Genrx Pharmaceuticals Private Limited (in Liquidation) (Genrx) on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act 1956. The acquisition was made for a total consideration of Rs. 1085.00 lakhs. <br /> Subsequently on 3 June 2025 the Company filed an application with the Honble National Company Law Tribunal (NCLT) Mumbai seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern which is pending with NCLT as on 30 June 2026. Hence Genrx has not been considered a subsidiary for consolidation purpose pending requisite approvals from the NCLT as control defined under Ind AS 110 Consolidated Financial Statements is not established. <br /> <br /> <br /> Debt Service Coverage Ratio is annualizedInterest Service Coverage Ratio indicates adequate coverage of finance costs.Brokerage & Commission10182000Consumption of Stores Spares and Maintainence67325000Freight Forwarding & Transport35856000Legal & Professional Expenses17516000Miscellaneous Expenses5750000Power and Fuel74807000Processing & Labour Charges58099000Provision for Credit Loss10000000Travelling & Conveyence Expenses6683000Others46903000Remeasurement of defined benefit plans3000000300000075500002245000OthersAllotment of Equity Shares pursuant to the exercise of options for conversion of convertible warrants into equity shares2026-03-185271300002026-06-30trueCARE Ratings LimitedfalseNot ApplicableNo CommentsNo CommentsRohan ParekhChief Financial OfficerThane2026-07-20Repayment & Prepayment of Secured/Unsecured Loans from Bank/NBFC in part or in fullNot Applicable1500000000150000000015000000000Investment in Capital ExpenditureNot Applicable3500000003500000002330840000General Corporate PurposeNot Applicable2200000001997000001993480000